Journal Home > Volume 2 , Issue 1
Cancer Innovation 2023, 2(1): 18-24 https://doi.org/10.1002/cai2.55
Review | Open Access | Issue | Published: 24 February 2023

Recent advances in immunotherapy for lung cancer

Show Author's Information Qi Wang,  Chunxia Su,  Caicun Zhou( )
Department of Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China

Qi Wang and Chunxia Su contributed equally to this study and shared the first authorship.

Keywords:
nonsmall cell lung cancer, small cell lung cancer, perioperative period, late stage, new immunotherapy
Cite this article:
Wang Q, Su C, Zhou C. Recent advances in immunotherapy for lung cancer. Cancer Innovation, 2023, 2(1): 18-24. https://doi.org/10.1002/cai2.55
Download citation
EndNote(RIS)
BibTeX

807

Views

82

Downloads

Citations

2

Crossref

N/A

WoS

1

Scopus

N/A

CSCD

Abstract Full text About this article

Lung cancer is the malignant tumor with the highest morbidity and mortality in China, and nonsmall cell lung cancer is a common form of lung cancer. After undergoing chemotherapy and molecular targeted therapy, the treatment of lung cancer has now fully entered the era of immunotherapy. Immunotherapy‐based treatment has become one of the standard treatments for lung cancer. Immunotherapy has also gradually moved from the back line to the front line, from advanced to early patients. This article focuses on the latest developments in perioperative and advanced lung cancer immunotherapy, discusses the problems and challenges at the current stage, and explores new directions for future development.


menu
Abstract
Full text
Outline
About this article

Recent advances in immunotherapy for lung cancer

Show Author's information Qi Wang, Chunxia Su, Caicun Zhou( )
Department of Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China

Qi Wang and Chunxia Su contributed equally to this study and shared the first authorship.

Abstract

Lung cancer is the malignant tumor with the highest morbidity and mortality in China, and nonsmall cell lung cancer is a common form of lung cancer. After undergoing chemotherapy and molecular targeted therapy, the treatment of lung cancer has now fully entered the era of immunotherapy. Immunotherapy‐based treatment has become one of the standard treatments for lung cancer. Immunotherapy has also gradually moved from the back line to the front line, from advanced to early patients. This article focuses on the latest developments in perioperative and advanced lung cancer immunotherapy, discusses the problems and challenges at the current stage, and explores new directions for future development.

Keywords: nonsmall cell lung cancer, small cell lung cancer, perioperative period, late stage, new immunotherapy

References(28)

1

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1): 7–33. https://doi.org/10.3322/caac.21654
DOI Google Scholar
2

Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non‐small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5): 584–94. https://doi.org/10.4065/83.5.584
DOI Google Scholar
3

Yang CY, Yang JCH, Yang PC. Precision management of advanced non‐small cell lung cancer. Annu Rev Med. 2020;71: 117–36. https://doi.org/10.1146/annurev-med-051718-013524
DOI Google Scholar
4

Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB‐IIIA non‐small‐cell lung cancer (IMpower010): a randomised, multicentre, open‐label, phase 3 trial. Lancet. 2021;398(10308): 1344–57. https://doi.org/10.1016/S0140-6736(21)02098-5
DOI Google Scholar
5

O'Brien M, Paz‐Ares L, Marreaud S, Dafni U, Oselin K, Havel L, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB‐IIIA non‐small‐cell lung cancer (PEARLS/KEYNOTE‐091): an interim analysis of a randomised, triple‐blind, phase 3 trial. Lancet Oncol. 2022;23(10): 1274–86. https://doi.org/10.1016/S1470-2045(22)00518-6
DOI Google Scholar
6

Provencio M, Serna‐Blasco R, Nadal E, Insa A, García‐Campelo MR, Casal Rubio J, et al. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non‐small‐cell lung cancer (NADIM phase II trial). J Clin Oncol. 2022;40(25): 2924–33. https://doi.org/10.1200/JCO.21.02660
DOI Google Scholar
7

Raboso‐Moreno B, de la Viña JI, Gato‐Díaz P, Jiménez‐Fernández M, Olaiz‐Navarro B. NADIM II study: what is the ideal time for surgery in Stage IIIA lung cancer. Arch Bronconeumol. 2022;S0300‐2896(22): 00574–9. https://doi.org/10.1016/j.arbres.2022.08.014
DOI Google Scholar
8

Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, et al. Five‐Year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non‐small‐cell lung cancer. J Clin Oncol. 2021;39(7): 723–33. https://doi.org/10.1200/JCO.20.01605
DOI Google Scholar
9

Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, et al. Nivolumab versus docetaxel in previously treated advanced non‐small‐cell lung cancer (CheckMate 017 and CheckMate 057): 3‐year update and outcomes in patients with liver metastases. Ann Oncol. 2018;29(4): 959–65. https://doi.org/10.1093/annonc/mdy041
DOI Google Scholar
10

Reck M, Rodríguez–Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Updated analysis of KEYNOTE‐024: pembrolizumab versus Platinum‐Based chemotherapy for advanced non‐small‐cell lung cancer with PD‐L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7): 537–46. https://doi.org/10.1200/JCO.18.00149
DOI Google Scholar
11

Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy‐naive patients with advanced non‐squamous non‐small‐cell lung cancer (CameL): a randomised, open‐label, multicentre, phase 3 trial. Lancet Respir Med. 2021;9(3): 305–14. https://doi.org/10.1016/S2213-2600(20)30365-9
DOI Google Scholar
12

Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G, et al. Camrelizumab plus carboplatin and paclitaxel as first‐Line treatment for advanced squamous NSCLC (CameL‐Sq): a phase 3 trial. J Thorac Oncol. 2022;17(4): 544–57. https://doi.org/10.1016/j.jtho.2021.11.018
DOI Google Scholar
13

Rodríguez‐Abreu D, Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Felip E, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol‐specified final analysis from KEYNOTE‐189. Ann Oncol. 2021;32(7): 881–95. https://doi.org/10.1016/j.annonc.2021.04.008
DOI Google Scholar
14

Paz‐Ares L, Vicente D, Tafreshi A, Robinson A, Soto Parra H, Mazières J, et al. A randomized, Placebo‐Controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol‐Specified final analysis of KEYNOTE‐407. J Thorac Oncol. 2020;15(10): 1657–69. https://doi.org/10.1016/j.jtho.2020.06.015
DOI Google Scholar
15

Paz‐Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, et al. First‐line nivolumab plus ipilimumab in advanced NSCLC: 4‐Year outcomes from the randomized, open‐label, phase 3 CheckMate 227 part 1 trial. J Thorac Oncol. 2022;17(2): 289–308. https://doi.org/10.1016/j.jtho.2021.09.010
DOI Google Scholar
16

Paz‐Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First‐line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non‐small‐cell lung cancer (CheckMate 9LA): an international, randomised, open‐label, phase 3 trial. Lancet Oncol. 2021;22(2): 198–211. https://doi.org/10.1016/S1470-2045(20)30641-0
DOI Google Scholar
17

Boyer M, Şendur MAN, Rodríguez‐Abreu D, Park K, Lee DH, Çiçin I, et al. Pembrolizumab plus ipilimumab or placebo for metastatic non‐small‐cell lung cancer with PD‐L1 tumor proportion score ≥50%: randomized, double‐blind phase III KEYNOTE‐598 study. J Clin Oncol. 2021;39(21): 2327–38. https://doi.org/10.1200/JCO.20.03579
DOI Google Scholar
18

D'Andrea AD. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair. 2018;71: 172–6. https://doi.org/10.1016/j.dnarep.2018.08.021
DOI Google Scholar
19

Brandts J, Ray KK. Clinical implications and outcomes of the ORION phase III trials. Future Cardiol. 2021;17(5): 769–77. https://doi.org/10.2217/fca-2020-0150
DOI Google Scholar
TROP2 ADC Intrigues in NSCLC. Cancer Discov 2021, 11(5): OF5. https://doi.org/10.1158/2159-8290.CD-NB2021-0314
DOI
21

Zhang J, Yi J, Zhou P. Development of bispecific antibodies in China: overview and prospects. Antibody therapeutics. 2020;3(2): 126–45. https://doi.org/10.1093/abt/tbaa011
DOI Google Scholar
22

Parums DV. Editorial: global regulatory initiatives deliver accelerated approval of the first bispecific therapeutic monoclonal antibody for advanced non‐small cell lung cancer (NSCLC. Med Sci Monit. 2021;27:e934854. https://doi.org/10.12659/MSM.934854
DOI Google Scholar
23

Qu T, Zhong T, Pang X, Huang Z, Jin C, Wang ZM, et al. Ligufalimab, a novel anti‐CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. J Immunother Cancer. 2022;10(11): e005517. https://doi.org/10.1136/jitc-2022-005517
DOI Google Scholar
24

Goldman JW, Garassino MC, Chen Y, Özgüroğlu M, Dvorkin M, Trukhin D, et al. Patient‐reported outcomes with first‐line durvalumab plus platinum‐etoposide versus platinum‐etoposide in extensive‐stage small‐cell lung cancer (CASPIAN): a randomized, controlled, open‐label, phase III study. Lung Cancer. 2020;149:46–52. https://doi.org/10.1016/j.lungcan.2020.09.003
DOI Google Scholar
25

Paz‐Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, et al. Durvalumab, with or without tremelimumab, plus platinum‐etoposide in first‐line treatment of extensive‐stage small‐cell lung cancer: 3‐year overall survival update from CASPIAN. ESMO Open. 2022;7(2): 100408. https://doi.org/10.1016/j.esmoop.2022.100408
DOI Google Scholar
26

Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, et al. Pembrolizumab or placebo plus etoposide and platinum as First‐Line therapy for Extensive‐Stage Small‐Cell lung cancer: randomized, Double‐Blind, phase III KEYNOTE‐604 study. J Clin Oncol. 2020;38(21): 2369–79. https://doi.org/10.1200/JCO.20.00793
DOI Google Scholar
27

Laird J, Lok BH, Carney B, Kossatz S, de Stanchina E, Reiner T, et al. Positron‐Emission tomographic imaging of a fluorine 18‐Radiolabeled Poly(ADP‐Ribose) polymerase 1 inhibitor monitors the therapeutic efficacy of talazoparib in SCLC Patient‐Derived xenografts. J Thorac Oncol. 2019;14(10): 1743–52. https://doi.org/10.1016/j.jtho.2019.05.032
DOI Google Scholar
28

Wermke M, Felip E, Gambardella V, Kuboki Y, Morgensztern D, Hamed ZO, et al. Phase I trial of the DLL3/CD3 bispecific T‐cell engager BI 764532 in DLL3‐positive small‐cell lung cancer and neuroendocrine carcinomas. Future Oncol. 2022;18(24): 2639–49. https://doi.org/10.2217/fon-2022-0196
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 10 December 2022
Accepted: 01 February 2023
Published: 24 February 2023
Issue date: February 2023

Copyright

© 2023 The Authors. Cancer Innovation published by John Wiley & Sons Ltd. on behalf of Tsinghua University Press.

Acknowledgements

ACKNOWLEDGMENTS

None.

Rights and permissions

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Return